Rethinking eligibility creep

J Am Acad Dermatol. 2008 Jul;59(1):165-7; author reply 167. doi: 10.1016/j.jaad.2008.02.041.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Controlled Clinical Trials as Topic
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Patient Selection*
  • Placebo Effect*
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Infliximab
  • Adalimumab